Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease

A compound of Formula VIb1:

• or a pharmaceutically acceptable salt thereof,
• wherein:
• R1b1 is 2-pyridinyl;
• R8b1 is hydrogen or methyl;
• R9b1 is phenyl, thienyl, pyridinyl, quinolinyl, heterocyclyl, or C(O)NR6R7;
• and
• R6 and R7 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, or heterocycloalkyl, or R6 and R7 are combined to form a cyclic structure including the nitrogen atom to which they are both attached;
• or
• wherein:
• R1b1 is 2-pyridinyl;
• R8b1 is hydrogen, methyl, —COOH, or —COOCH3;
• R9b1 is selected from the group consisting of cyclobutyl, —CO2CH3, piperidin-4-ylmethyl, piperidin-3-ylmethyl, 2-chlorophenyl,
• or
• wherein:
• R1b1 is pyridinyl;
• R8b1 is
• and
• R9b1 is hydrogen, methyl, —COOH, or —COOCH3;
• or
• wherein:
• R1b1 is aryl, heteroaryl, or NR6R7;
• R8b1 is C(O)R4;
• R9b1 is alkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, halo, pseudohalo, C(O)R4, or S(O)pR4;
• R4 is hydrogen, hydroxy, alkyl, haloalkyl, alkenyl, alkynyl, aryl, alkylaryl, heterocyclyl, cycloalkyl, aralkyl, alkoxy, alkenyloxy, alkynyloxy, aryloxy, alkylaryloxy, heterocyclyloxy, cycloalkyloxy, aralkoxy, or —NR6R7;
• R6 and R7 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, arylsulfonyl, heteroarylsulfonyl, cycloalkylsulfonyl or alkylsulfonyl, or R6 and R7 are combined to form a cyclic structure including the nitrogen atom to which they are both attached;
• p is 0-2;
• or
• wherein the compound is:
• or a pharmaceutically acceptable salt thereof.